Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
vosilasarm + elacestrant
- Development stage
- Phase 2
- Lead developer
- Ellipses Pharma
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**Vosilasarm + elacestrant** is an investigational oral combination therapy under clinical evaluation for the treatment of advanced or metastatic androgen receptor-positive, HER2-negative, estrogen receptor-positive (AR+/HER2-/ER+) breast cancer. Vosilasarm (code name EP0062) is a selective androgen receptor modulator (SARM) that may provide antitumor activity through modulation of androgen receptor signaling in breast cancer. Elacestrant is an oral selective estrogen receptor degrader (SERD) that promotes degradation of the estrogen receptor and inhibits its signaling, which is a validated approach in the treatment of ER-positive breast cancer, including subpopulations with ESR1 mutation-driven resistance to endocrine therapies. This combination is being studied to evaluate synergistic effects and overcome endocrine resistance.
- Other names
- vosilasarm + elacestrant
02
Targets
AR (Adrenergic receptors)ESR1 (ERα)
Beyond the preview
Go deeper on vosilasarm + elacestrant.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on vosilasarm + elacestrant.